philadelphia-negative b-precursor acute lyphmoblastic leukemia in complete hematological remission
Item
patients with philadelphia-negative b-precursor acute lyphmoblastic leukemia in complete hematological remission defined as less than 5 percent blasts in bone marrow after at least 3 intensive chemotherapy blocks (i.e. any standard or investigational regimen according to adult protocols as long as 3 age appropriate chemotherapy blocks were given, this also includes relapse treatment
boolean
C1960645 (UMLS CUI [1])
C0457341 (UMLS CUI [2])
detection of minimal residual disease
Item
detection of minimal residual disease (molecular failure or molecular relapse) at a level of greater than or equal to 10*(-4) by pcr or greater than or equal to 10*(-3) by flow cytometry at a reference lab
boolean
C1511791 (UMLS CUI [1])
age
Item
age 15 or greater at time of initial diagnosis with acute lymphoblastic leukemia. for patients aged 15-17 treatment according to adult protocols is required
boolean
C0001779 (UMLS CUI [1])
initial diagnosis
Item
initial diagnosis in the year 2000 or later
boolean
C0011900 (UMLS CUI [1])
C0332168 (UMLS CUI [2])
patient medical history
Item
history of acute lymphoblastic leukemia treatment (including response to first therapy, number of prior relapses) is available
boolean
C0262926 (UMLS CUI [1])
relapse status and disease follow up
Item
relapse status and disease follow up after timepoint of minimal residual disease detection is available
boolean
C1277192 (UMLS CUI [1])
C0589120 (UMLS CUI [2])
extramedullary disease
Item
patients with extramedullary disease at timepoint of minimal residual disease detection
boolean
C1868812 (UMLS CUI [1])
blinatumomab
Item
use of blinatumomab within 18 months of minimal residual disease detection
boolean
C3853839 (UMLS CUI [1])
allogeneic hematopoietic stem cell transplantation
Item
allogeneic hematopoietic stem cell transplantation prior to minimal residual disease detection at the required level
boolean
C2242529 (UMLS CUI [1])